GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company, today announced that its GEO-MVA vaccine platform strategy closely aligns with the priorities outlined in the U.S. Department of Health and Human Services Administration for Strategic Preparedness and Response's (ASPR) newly released Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) Multiyear Budget: Fiscal Years 2025–2029. The report provides a five-year roadmap for investments in medical countermeasures, advanced manufacturing, Strategic National Stockpile (SNS) modernization, and preparedness against emerging infectious diseases and biological threats.
According to the report, approximately 65% of future medical countermeasure investment will focus on threat-agnostic and multi-threat technologies, with an emphasis on domestic manufacturing capability, scalable vaccine platforms, and sustained preparedness infrastructure. The report projects a total five-year investment need of approximately $66.9 billion, underscoring the growing strategic importance of resilient domestic biodefense capabilities.
“The release of ASPR's five-year preparedness strategy reinforces many of the strategic priorities that have guided our GEO-MVA program,” said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. “The report recognizes that future preparedness requires more than individual vaccines - it requires flexible platform technologies, domestic manufacturing capability, resilient supply chains, and sustainable medical countermeasure infrastructure. GEO-MVA has been developed with these national priorities in mind.”
GeoVax identified several ASPR priorities that directly support the long-term strategic rationale of the GEO-MVA program. Regarding domestic manufacturing, the ASPR report identifies sustaining and expanding U.S.-based commercial manufacturing capability as a principal preparedness challenge. GeoVax's GEO-MVA program aims to establish a U.S.-based source of Modified Vaccinia Ankara (MVA) vaccine manufacturing, supporting domestic supply-chain resilience and reducing dependence on limited global capacity.
On platform technologies, the report emphasizes investments in threat-agnostic and multi-threat technologies capable of rapid response. The MVA vector is a well-established vaccine platform with demonstrated applicability across multiple infectious disease targets, providing flexibility beyond any single indication. For the Strategic National Stockpile, the ASPR strategy calls for continued modernization, lifecycle management, and replenishment. GeoVax believes GEO-MVA aligns by supporting future U.S. preparedness for orthopoxvirus threats.
Regarding emerging infectious diseases, the report identifies them as the highest preparedness priorities. GeoVax's clinical development strategy for GEO-MVA is intended to support preparedness against mpox and smallpox while leveraging the broader MVA platform capabilities. The ASPR report reflects an evolution from investing primarily in individual products toward investing in strategic capabilities, including manufacturing infrastructure and platform technologies.
“Preparedness is increasingly being viewed as a strategic national capability rather than simply a collection of products,” added Mr. Dodd. “We believe this evolution supports the importance of maintaining flexible vaccine platforms and domestic manufacturing infrastructure capable of responding to future biological threats.”
GeoVax's GEO-MVA is a Modified Vaccinia Ankara (MVA) vaccine candidate being developed for protection against mpox and smallpox. The program is advancing through an immunobridging regulatory strategy following positive Scientific Advice from the European Medicines Agency and is intended to provide an additional source of MVA vaccine manufacturing capacity for future public health preparedness initiatives. More information is available at www.geovax.com.
